🇺🇸 FDA
Pipeline program

REGV131

R131L1265-HEMB-2318

Phase 2 small_molecule active

Quick answer

REGV131 for Hemophilia B is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Hemophilia B
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials